10x Genomics Management
Management criteria checks 4/4
10x Genomics' CEO is Serge Saxonov, appointed in Jul 2012, has a tenure of 14.17 years. total yearly compensation is $6.33M, comprised of 10.7% salary and 89.3% bonuses, including company stock and options. directly owns 3.18% of the company’s shares, worth $316.88M. The average tenure of the management team and the board of directors is 2.7 years and 7.3 years respectively.
Key information
Serge Saxonov
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 10.65% |
| CEO tenure | 14.2yrs |
| CEO ownership | 3.2% |
| Management average tenure | 2.7yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Narrative Update • Sep 17
TXG: Rich Multiples Will Clash With Slower Single Cell Recovery Expectations
The analyst price target framework for 10x Genomics has shifted higher, with fair value moving from $17.00 to $40.00 as analysts factor in updated growth assumptions, higher projected profit margins, and richer sector P/E multiples supported by recent research that highlights Atera demand, consumable durability, and the broader life science tools backdrop. Analyst Commentary Recent research coverage on 10x Genomics shows a mix of optimism around new products and a more measured stance on the company’s more established lines of business.
Narrative Update • Sep 03
TXG: Cancer Collaborations And AI Drug Discovery Uses Will Shape Balanced Outlook
The analyst price target for 10x Genomics has moved from $50 to about $68, with analysts pointing to updated models that reflect the Atera launch, spatial and consumables demand, and the company's positioning around AI driven drug development as key supports for the higher valuation assumptions. Analyst Commentary Recent Street research on 10x Genomics points to a cluster of price target increases tied to Atera, spatial biology adoption, and updated revenue models.
Narrative Update • Aug 20
TXG: Elevated AI Demand Expectations Will Pressure Overextended Near Term Setup
Analysts have lifted the fair value estimate for 10x Genomics from $41.54 to $49.54, reflecting a series of higher price targets that reference stronger revenue assumptions, slightly improved profit margins, and interest in the company's role in AI driven drug development and Atera demand. Analyst Commentary Recent Street research on 10x Genomics points to a mix of optimism and caution.Seeking Alpha • Aug 20
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)
Summary Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG’s valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution. Read the full article on Seeking AlphaAnalysis Article • Aug 12
US$49.54 - That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results
A week ago, 10x Genomics, Inc. ( NASDAQ:TXG ) came out with a strong set of quarterly numbers that could potentially...Narrative Update • Aug 06
TXG: Elevated 2027 Expectations And Product Transitions Will Pressure Near Term Setup
Analyst price targets for 10x Genomics have moved sharply higher, with the fair value estimate rising from about $20.14 to $41.54 as analysts factor in higher sector multiples, expectations around single cell demand, and potential contribution from the Atera platform in coming years. Analyst Commentary Recent research on 10x Genomics shows a cluster of higher price targets, but with mixed views on how much upside is left relative to execution risk and current valuation levels.Narrative Update • Jul 23
TXG: Cancer Collaboration And Tools Strength Will Support Balanced Outlook
The analyst price target for 10x Genomics has been raised from $45.00 to $50.00. Analysts generally point to higher sector multiples, expectations that single cell and the Atera platform could support future demand, and updated earnings models ahead of upcoming results as key reasons for the change.Narrative Update • Jul 09
TXG: Cancer Collaboration And Spatial Rollout Will Support More Constructive Outlook
Analysts have lifted the 10x Genomics fair value estimate from $40.00 to $45.00, reflecting higher Street price targets, including recent moves to $37 at Morgan Stanley, $40 at Barclays, and $45 at Citi. These changes are supported by updated earnings models and growing interest in life science tools.Narrative Update • Jun 25
TXG: Multiomic Cancer Collaboration And Spatial Launch Plans Will Support Bullish Outlook
Analysts have lifted the 10x Genomics fair value estimate to $40 from $32, reflecting a higher Street price target and modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions in recent research updates across the tools sector. Analyst Commentary Recent research on 10x Genomics reflects a cluster of bullish adjustments to price targets and ratings across the life science tools space, with several bullish analysts flagging the stock as a relative bright spot within healthcare tools and diagnostics.Narrative Update • Jun 11
TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook
Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.Narrative Update • May 28
TXG: Spatial Consumables And Spatial Partnerships Will Support Atera-Led Upside In 2026
Analysts have lifted their price targets on 10x Genomics by single digit dollar amounts, citing more constructive views on revenue growth, margins and the competitive setup. This feeds into a refreshed valuation framework even as the internal fair value estimate stays at $32.00 per share.Analysis Article • May 13
Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results
10x Genomics, Inc. ( NASDAQ:TXG ) just released its latest quarterly results and things are looking bullish. Revenues...Narrative Update • May 12
TXG: 2026 Academic Demand Weakness Will Challenge Elevated Expectations
Analysts have raised 10x Genomics' consolidated price target by several dollars into the mid $20s, citing improving expectations for revenue growth, modestly higher profit margins, and recent research that points to steady new product adoption and a more favorable competitive environment. Analyst Commentary Recent Street research on 10x Genomics has largely centered on a series of price target revisions tied to product adoption trends, funding visibility and the mix between instruments and consumables.Narrative Update • Apr 21
TXG: Spatial Consumables Strength Will Offset Instrument Softness In 2026
The analyst price target for 10x Genomics has shifted from about $24 to $32, with analysts pointing to recent target hikes across multiple firms that reflect updated views on product adoption, competitive positioning in single cell, and mixed trends across instrument and consumables demand. Analyst Commentary Recent research shows a cluster of bullish analysts increasing their price targets on 10x Genomics, as well as at least one upgrade, pointing to a more constructive stance on the story.Narrative Update • Apr 06
TXG: Spatial Consumables And New Product Uptake Will Shape 2026 Outlook
Analysts have raised their average price target on 10x Genomics from about $18 to roughly $24, citing solid new product adoption, a favorable competitive setup in single cell, and expectations that pressure in instruments and single cell consumables could be partly offset by growth in spatial consumables. Analyst Commentary Recent research updates show a cluster of bullish analysts lifting price targets on 10x Genomics, with new targets cited at about $18, $20 and $25.Narrative Update • Mar 23
TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup
Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.Narrative Update • Mar 07
TXG: 2026 Academic Weakness And Pricing Pressure Will Test Elevated Expectations
Analysts have inched up their price targets on 10x Genomics, with moves such as $14 to $20 at UBS, $15 to $18 at TD Cowen and $20 to $25 at Stifel. These changes reflect a mix of confidence in new product adoption, a favorable single cell competitive setup, and expectations that spatial consumables can help offset pressure in single cell consumables and softer academic instrument demand.Narrative Update • Feb 21
TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment
The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.Narrative Update • Feb 07
TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside
Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space. Analyst Commentary Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral.Analysis Article • Jan 24
10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, 10x Genomics, Inc. ( NASDAQ:TXG ) shares have been powering on, with a gain of 34% in...Narrative Update • Jan 23
TXG: ARK Buying And Soft 2026 Outlook Will Restrain Upside Potential
Analysts have nudged their 10x Genomics price target higher to about $18, up from around $17.36. This reflects slightly updated fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, alongside recent Street research that includes an $18 target and continued institutional interest.Narrative Update • Jan 08
TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment
Analysts have raised their fair value estimate for 10x Genomics from US$9.00 to US$14.00, citing higher assumed revenue growth, a richer future P/E multiple, and recent Street research that highlights an increased price target in the life science tools space. Analyst Commentary Recent research in the life science tools space has highlighted a cautious tone around near term expectations for 10x Genomics, even as some price targets have been adjusted.Narrative Update • Dec 25
TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance
Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.Narrative Update • Dec 11
TXG: ARK Buying And Product Advances Will Shape Balanced Risk Reward Outlook
Analysts have nudged their price target for 10x Genomics slightly higher, from approximately 16.36 dollars to 16.57 dollars, citing incremental improvements in long term growth assumptions and renewed institutional interest following sizable recent share purchases. Analyst Commentary Analyst reaction to the latest moves in 10x Genomics stock has been mixed, with many highlighting both the opportunities created by recent institutional buying and the ongoing execution risks that could affect the company’s valuation trajectory.Narrative Update • Nov 27
TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure
Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.Analysis Article • Nov 14
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump
10x Genomics, Inc. ( NASDAQ:TXG ) shareholders would be excited to see that the share price has had a great month...Narrative Update • Nov 09
TXG: Institutional Interest And New Assay Expected To Influence Future Performance
Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.Narrative Update • Aug 08
Advanced Genomics Tools Will Shape Future Precision Medicine
Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$75m |
| Mar 31 2026 | n/a | n/a | -US$23m |
| Dec 31 2025 | US$6m | US$674k | -US$44m |
| Sep 30 2025 | n/a | n/a | -US$76m |
| Jun 30 2025 | n/a | n/a | -US$85m |
| Mar 31 2025 | n/a | n/a | -US$157m |
| Dec 31 2024 | US$8m | US$625k | -US$183m |
| Sep 30 2024 | n/a | n/a | -US$183m |
| Jun 30 2024 | n/a | n/a | -US$240m |
| Mar 31 2024 | n/a | n/a | -US$264m |
| Dec 31 2023 | US$8m | US$545k | -US$255m |
| Sep 30 2023 | n/a | n/a | -US$223m |
| Jun 30 2023 | n/a | n/a | -US$172m |
| Mar 31 2023 | n/a | n/a | -US$174m |
| Dec 31 2022 | US$19m | US$504k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$167m |
| Jun 30 2022 | n/a | n/a | -US$142m |
| Mar 31 2022 | n/a | n/a | -US$89m |
| Dec 31 2021 | US$12m | US$430k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$455m |
| Jun 30 2021 | n/a | n/a | -US$504m |
| Mar 31 2021 | n/a | n/a | -US$533m |
| Dec 31 2020 | US$11m | US$400k | -US$543m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$2m | US$394k | -US$31m |
Compensation vs Market: Serge's total compensation ($USD6.33M) is below average for companies of similar size in the US market ($USD14.74M).
Compensation vs Earnings: Serge's compensation has been consistent with company performance over the past year.
CEO
Serge Saxonov (49 yo)
14.2yrs
Tenure
US$6,329,244
Compensation
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.2yrs | US$6.33m | 3.18% $ 316.9m | |
| Co-Founder | 14.2yrs | US$2.60m | 2.55% $ 254.5m | |
| CFO, Treasurer | 2.1yrs | US$2.23m | 0.085% $ 8.4m | |
| Chief of Global Operations | 2.7yrs | no data | no data | |
| Founding Scientist & CTO | 4.7yrs | no data | no data | |
| Manager of Investor Relations & Strategic Finance | no data | no data | no data | |
| General Counsel and Secretary | less than a year | no data | no data | |
| Chief Commercial Officer | 2.1yrs | no data | no data | |
| Associate Director of Product Management | no data | no data | no data |
2.7yrs
Average Tenure
51yo
Average Age
Experienced Management: TXG's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.2yrs | US$6.33m | 3.18% $ 316.9m | |
| Co-Founder | 14.2yrs | US$2.60m | 2.55% $ 254.5m | |
| Independent Director | 6.5yrs | US$216.32k | 0.022% $ 2.2m | |
| Independent Chairman | 13.1yrs | US$283.41k | 1.86% $ 186.0m | |
| Independent Director | 7.1yrs | US$210.99k | 0.018% $ 1.8m | |
| Independent Director | 2.3yrs | US$208.27k | 0.052% $ 5.2m | |
| Independent Director | 7.4yrs | US$223.32k | 0.046% $ 4.6m | |
| Independent Director | 2.2yrs | US$198.32k | no data |
7.3yrs
Average Tenure
52.5yo
Average Age
Experienced Board: TXG's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 23:27 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
10x Genomics, Inc. is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Avantika Dhabaria | BofA Global Research |
| Michael Ryskin | BofA Global Research |